protac cbp/p300 degrader 1

PROTAC CBP/P300 Degrader-1 is an effective compound that potently degrades CBP/P300, significantly reducing cell viability in various cancer cell lines.

PROTAC CBP/p300/BRD4 Degrader-1 is a dual-targeting PROTAC degrader with DC50 values of 8.8 pM for BRD4, 6.55 nM for CBP, and 1.05 nM for p300. It facilitates CRBN and proteasome-dependent degradation of BRD4 and CBP/p300, leading to the downregulation of c-Myc and acetyl-H3K27, and triggers apoptosis. As an antiproliferative and antitumor agent, PROTAC CBP/p300/BRD4 Degrader-1 demonstrates tumor growth inhibition in xenograft models. It is applicable in research on prostate and colorectal cancers.

QC-182 is a potent p300/CBP PROTAC degrader. It reduces p300 protein levels in SK-HEP-1 cells with a DC50 of 93 nM. QC-182 effectively inhibits cell growth in SK-HEP-1 and JHH7 cell lines, with IC50 values of 0.733 μM and 0.477 μM, respectively. QC-182 is applicable for hepatocellular carcinoma (HCC) research.

CBP-IN-1 acid (Compound 48) is a synthetic E3 ligase ligand-linker conjugate, utilized in the synthesis of PROTACs like CBPD-268. CBPD-268 is a potent CBP/p300 PROTAC degrader with anticancer properties.

CBP/p300 ligand 2 is the target protein ligand for PROTAC dCBP-1, a potent and selective p300/CBP degrader.